Publications by authors named "J M Peron"

Claim this Profile
S
SALVOVAR: a pragmatic randomized phase III trial comparing the SALVage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic OVARian cancers.
Claire Chator, Nozomu Yanaihara, Sylvie Chabaud, Gabriella Maria Parma, Alexandra L Dima, Julien Peron

Ther Adv Med Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Features and Outcomes of 280 Patients With Idiosyncratic Drug-induced Liver Injury: The REFHEPS Prospective Study.
Lucy Meunier, Bénédicte Delire, Eleonora De Martin, Fanny Lebossé, Rodolphe Anty

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma.
Jean-Charles Nault, Claudia Campani, Theo Z Hirsch, Ethan Neumann, Waqar Arif, Jean-Marie Peron

medRxiv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study.
François Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, Jean-Marie Péron, Marilyne Debette-Gratien

Liver Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.
Pauline Corbaux, Benoit You, Tatsuo Kagimura, Rosalind M Glasspool, Iain McNeish

Int J Gynecol Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis